Changing landscape of invasive aspergillosis in allogeneic stem cell transplant recipients

Transplant Infectious Disease

Volumn 10, Issue 3, 2008, Pages 156-161

  Jantunen, E ^a   Nihtinen, A ^b   Anttila, V J ^b  

^a KUOPIO UNIVERSITY HOSPITAL   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Allogeneic stem cell transplantation; Diagnosis; Epidemiology; Invasive aspergillosis; Prophylaxis; Therapy

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; BETA GLUCAN; CASPOFUNGIN; CORTICOSTEROID; ECHINOCANDIN; FLUCONAZOLE; GALACTOMANNAN; GLUCOCORTICOID; ITRACONAZOLE; POSACONAZOLE; VORICONAZOLE;

ALLOGENEIC STEM CELL TRANSPLANTATION; ASPERGILLOSIS; CENTRAL NERVOUS SYSTEM; DONOR LYMPHOCYTE INFUSION; DRUG EFFICACY; DRUG INDICATION; DRUG MEGADOSE; DRUG SAFETY; EARLY DIAGNOSIS; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HISTOPATHOLOGY; HUMAN; INCIDENCE; LIVER TOXICITY; LUNG ASPERGILLOSIS; LUNG LAVAGE; MORTALITY; NEUTROPENIA; PATHOGENESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROPHYLAXIS; RECOMMENDED DRUG DOSE; RELAPSE; REVIEW; RISK FACTOR; STEM CELL; SURVIVAL; THORAX; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ANTIFUNGAL AGENTS; ASPERGILLOSIS; BRONCHOALVEOLAR LAVAGE FLUID; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSION; LEUKEMIA, MYELOID, ACUTE; MANNANS; POLYMERASE CHAIN REACTION; RISK FACTORS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 43949127407     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/j.1399-3062.2008.00301.x     Document Type: Review

References (59)

1. Gratwohl A, Baldomero H, Schmid O, Horisberger B, Bargetzi M, Urbano-Ispizua A. Changes in stem cell source for hematopoietic stem cell transplantation (HSCT) in Europe: a report of the EBMT activity survey 2003. Bone Marrow Transplant 2005 36 : 575 590.
2. Gratwohl A, Baldomero H, Frauendorfer K, Urbano-Ispizua A, Niederwieser D. Results of the EBMT activity survey 2005 on hematopoietic stem cell transplantation: focus on increasing use of unrelated donors. Bone Marrow Transplant 2007 39 : 71 87.
3. Jantunen E, Ruutu P, Niskanen L, et al. Incidence and risk factors for invasive fungal infections in allogeneic stem cell transplant recipients. Bone Marrow Transplant 1997 19 : 801 808.
4. Wald A, Leisenring W, van Burik JA, Bowden RA. Epidemiology of Aspergillus infections in a large cohort of patients undergoing allogeneic bone marrow transplantation. J Infect Dis 1997 175 : 1459 1466.
5. Marr KA, Carter RA, Boeckh M, Martin P, Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002 100 : 4358 4366.
6. Cornet M, Fleury L, Maslo C, Bernard JF, Brucker D. Epidemiology of invasive aspergillosis in France: a six-year multicentric survey in the Greater Paris area. J Hosp Infect 2002 51 : 288 296.
7. Thursky K, Byrnes G, Grigg A, Szer J, Slavin M. Risk factors for post-engraftment invasive aspergillosis in allogeneic stem cell transplantation. Bone Marrow Transplant 2004 34 : 115 121.
8. Seo KW, Kim DH, Sohn SK, et al. Protective role of interleukin-10 promoter gene polymorphism in the pathogenesis of invasive pulmonary aspergillosis after allogeneic stem cell transplantation. Bone Marrow Transplant 2005 36 : 1089 1095.
9. Martino R, Subira M, Rovira M, et al. Invasive fungal infections after allogeneic peripheral blood stem cell transplantation: incidence and risk factors in 395 patients. Br J Haematol 2002 116 : 475 482.
10. Jantunen E, Nihtinen A, Volin L, et al. Candidaemia in allogeneic stem cell transplant recipients: low risk without fluconazole prophylaxis. Bone Marrow Transplant 2004 34 : 891 895.
11. Nihtinen A, Volin L, Anttila V-J, Juvonen E, Ruutu T. Relapse of acute leukaemia or myelodysplastic syndrome after an allogeneic stem cell transplantation: increased risk of invasive mould infections. Bone Marrow Transplant 2007 39 (Suppl 1) : S176.
12. Morgan J, Wannemuehler KA, Marr KA, et al. Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: interim results of a prospective multicenter surveillance program. Med Mycol 2005 43 (Suppl 1) : S49 S58.
13. Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002 34 : 7 14.
14. Mihu CN, King E, Yossepovitch O, et al. Risk factors and attributable mortality of late aspergillosis after T-cell depleted hematopoietic stem cell transplantation. Transpl Infect Dis 2008 10 (3 162 167.
15. Kontoyiannis DP, Chamilos G, Lewis RE, et al. Increased bone marrow iron stores is an independent risk factor for invasive aspergillosis in patients with high-risk hematologic malignancies and recipients of allogeneic stem cell transplantation. Cancer 2007 110 : 1303 1306.
16. Fukuda T, Boekh M, Carter RA, et al. Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after myeloablative conditioning. Blood 2003 102 : 827 833.
17. Kojima R, Kami M, Nannya Y, et al. Incidence of invasive aspergillosis after allogeneic hematopoietic stem cell transplantation with a reduced-intensity regimen compared with transplantation with a conventional regimen. Biol Blood Marrow Transplant 2004 10 : 645 652.
18. Miyakoshi S, Kusumi E, Matsumura T, et al. Invasive fungal infection following reduced-intensity cord blood transplantation for adult patients with hematologic diseases. Biol Blood Marrow Transplant 2007 13 : 771 717.
19. Baddley JW, Stroud TP, Salzman D, Pappas PG. Invasive mold infections in allogeneic bone marrow transplant recipients. Clin Infect Dis 2001 32 : 1319 1324.
20. Upton A, Kirby KA, Carpenter P, Boeckh M, Marr KA. Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. Clin Infect Dis 2007 44 : 531 540.
21. Jantunen E, Volin L, Salonen O, et al. Central nervous system aspergillosis in allogeneic stem cell transplant recipients. Bone Marrow Transplant 2003 31 : 191 196.
22. Horger M, Hebart H, Einsele H, et al. Initial CT manifestations of invasive pulmonary aspergillosis in 45 non-HIV immunocompromised patients. Eur J Radiol 2005 55 : 437 444.
23. Caillot D, Couaillier JF, Bernard A, et al. Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. J Clin Oncol 2001 19 : 253 259.
24. Greene RE, Schlamm HT, Oestmann JW, et al. Imaging findings in acute invasive aspergillosis: clinical significance of the halo sign. Clin Infect Dis 2007 44 : 373 379.
25. Kojima R, Tateishi U, Kami M, et al. Chest computed tomography of late invasive aspergillosis after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005 11 : 506 511.
26. Sanguinetti M, Posteraro B, Pagano L, et al. Comparison of real-time PCR, conventional PCR, and galactomannan antigen detection by enzyme-linked immunosorbent assay using bronchoalveolar lavage fluid samples from haematology patients for diagnosis of invasive pulmonary aspergillosis. J Clin Microbiol 2003 41 : 3922 3925.
27. Musher B, Fredericks D, Leisenring W, Balajee SA, Smith C, Marr KA. Aspergillus galactomannan enzyme immunoassay and quantitative PCR for diagnosis of invasive aspergillosis with bronchoalveolar fluid. J Clin Microbiol 2004 42 : 5517 5512.
28. Hohenthal U, Itälä M, Salonen J, et al. Bronchoalveolar lavage in immunocompromised patients with haematological malignancy - value of new microbiological methods. Eur J Haematol 2005 74 : 203 211.
29. Maertens J, van Eldere J, Verhaegen J, Verbeken E, Verschalkelen J, Boogaerts M. Use of circulating galactomannan screening for early diagnosis of invasive aspergillosis in allogeneic stem cell transplant recipients. J Infect Dis 2002 186 : 1297 1306.
30. Maertens J, Theunissen K, Verbeken E, et al. Prospective clinical evaluation of lower cut-offs for galactomannan detection in adult neutropenic cancer patients and haematological stem cell transplant recipients. Br J Haematol 2004 126 : 852 860.
31. Maertens J, Theunissen K, Verhoef G, et al. Galactomannan and computed tomography-based pre-emptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis 2005 41 : 1242 1250.
32. Weisser M, Rausch C, Droll A, et al. Galactomannan does not precede major signs on a pulmonary computerized tomographic scan suggestive of invasive aspergillosis in patients with haematological malignancies. Clin Infect Dis 2005 41 : 1143 1149.
33. Busca A, Locatelli F, Barbui A, et al. Usefulness of sequential galactomannan antigen detection combined with early radiologic evaluation for diagnosis of invasive pulmonary aspergillosis in patients undergoing allogeneic stem cell transplantation. Transplant Proc 2006 38 : 1610 1613.
34. Aubry A, Porcher R, Bottero J, et al. Occurrence and kinetics of false positive Aspergillus galactomannan test results following treatment with beta-lactam antibiotics in patients with haematological disorders. J Clin Microbiol 2006 44 : 389 394.
35. Marr KA, Laverdiere M, Gugel A, Leisenring W. Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay. Clin Infect Dis 2005 40 : 1762 1769.
36. Halliday C, Hoile R, Sorrell T, et al. Role of prospective screening of blood for invasive aspergillosis by polymerase chain reaction in febrile neutropenic recipients of haematopoietic stem cell transplants and patients with acute leukaemia. Br J Haematol 2006 132 : 478 486.
37. White PL, Linton CJ, Perry MD, Johnson EM, Barnes RA. The evolution and evaluation of a whole blood polymerase chain reaction assay for the detection of invasive aspergillosis in haematology patients in a routine clinical setting. Clin Infect Dis 2006 42 : 479 486.
38. Schabereiter-Gurtner C, Selitsch B, Rotter ML, Hirschl AM, Willinger B. Development of novel real-time PCR assays for detection and differentiation of eleven medically important Aspergillus and Candida species in clinical specimens. J Clin Microbiol 2007 45 : 905 914.
39. Rickerts V, Mousset S, Lambrecht E, et al. Comparison of histopathological analysis, culture, and polymerase chain reaction assays to detect invasive mold infections from biopsy specimens. Clin Infect Dis 2007 44 : 1078 1083.
40. Ostrosky-Zeichner L, Alexander BD, Kett DH, et al. Multicenter clinical evaluation of the (1→3) beta D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis 2005 41 : 654 659.
41. Pickering JW, Sant HW, Bowles CA, Roberts WL, Woods GL. Evaluation of a (1→3)-beta-d-glucan assay for diagnosis of invasive fungal infections. J Clin Microbiol 2005 43 : 5957 5962.
42. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002 347 : 408 415.
43. Schwartz S, Ruhnke M, Ribaud P, et al. Improved outcome in central nervous system aspergillosis using voriconazole treatment. Blood 2005 106 : 2641 2645.
44. Steinbach WJ, Benjamin DK Jr., Kontoyannis DP, et al. Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases. Clin Infect Dis 2004 39 : 192 198.
45. Herbrecht R, Flueckiger U, Gachot B, et al. Treatment of invasive Candida and invasive Aspergillus infections in adult haematological patients. Eur J Cancer Suppl 2007 5 : 49 59.
46. Walsh TJ, Raad I, Patterson TF, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 2007 44 : 2 12.
47. Maertens J, Raad I, Petrikkos G, et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004 39 : 1563 1571.
48. Maertens J, Glasmacher A, Herbrecht R, et al. Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis. Cancer 2006 107 : 2888 2897.
49. Safdar A, Rodriguez G, Rolston KV, et al. High-dose caspofungin combination antifungal therapy in patients with hematologic malignancies and hematopoietic stem cell transplantation. Bone Marrow Transplant 2007 39 : 157 164.
50. Denning DW, Marr KA, Lau WM, et al. Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J Infect 2006 53 : 337 349.
51. Marr KA, Boeckh M, Carter RA, Kim HW, Corey L. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 2004 39 : 797 802.
52. Boutboul F, Alberti C, Lebranc T, et al. Invasive aspergillosis in allogeneic stem cell transplant recipients: increasing antigenemia is associated with progressive disease. Clin Infect Dis 2002 34 : 939 943.
53. Cordonnier C, Ribaud P, Herbrecht R, et al. Prognostic factors for death due to invasive aspergillosis after hematopoietic stem cell transplantation: a 1-year retrospective study of consecutive patients at French transplantation centres. Clin Infect Dis 2006 42 : 955 963.
54. Nihtinen A, Anttila V-J, Richardson M, Meri T, Volin L, Ruutu T. The utility of intensified environmental surveillance for pathogenic moulds in a stem cell transplantation ward during construction work to monitor the efficacy of HEPA filtration. Bone Marrow Transplant 2007 40 : 457 460.
55. Winston DJ, Maziarz RT, Chandrasekar PH, et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial. Ann Intern Med 2003 138 : 705 713.
56. Marr KA, Crippa F, Leisenring W, et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood 2004 103 : 1527 1533.
57. Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007 356 : 335 347.
58. Maertens JA, Frere P, Lass-Flörl C, Heiz W, Cornely OA. Primary antifungal prophylaxis in leukaemia patients. Eur J Cancer Suppl 2007 5 : 43 48.
59. Schmitz N, Eapen M, Horowitz MM, et al. Long-term outcome of patients given transplants of mobilized blood or bone marrow: a report from the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. Blood 2006 108 : 4288 4290.